PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, “PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly’s blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.
These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.
This lack of growth will be due mainly to price cuts. While patent expiries will eat into the sales of branded drugs, the effect will not be as drastic as in other markets. In addition, because the Japanese regulatory system requires safety trials to be conducted in Japanese patients, pipeline products will launch later in this country than in the other six major markets. Therefore, it is likely that there will be further growth in the market beyond the 10-year forecast period. This next generation of drugs consists largely of biologics, which will be priced higher than the drugs losing patent protection in the first half of the forecast period.
Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Japan from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting Japan Osteoporosis market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in Japan